The fungus Aspergillus fumigatus is ubiquitous in nature and the most common cause of invasive pulmonary aspergillosis (IPA) in patients with a compromised immune system. The development of IPA in patients under immunosuppressive treatment or in patients with primary immunodeficiency demonstrates the importance of the host immune response in controlling aspergillosis. However, study of the host-microbe interaction has been hampered by the lack of tools for their non-invasive assessment. We developed a methodology to study the response of the host's immune system against IPA longitudinally in vivo by using fluorine-19 magnetic resonance imaging ( 19 F MRI). We showed the advantage of a perfluorocarbon-based contrast agent for the in vivo labeling of macrophages and dendritic cells, permitting quantification of pulmonary inflammation in different murine IPA models. Our findings reveal the potential of 19 F MRI for the assessment of rapid kinetics of innate immune response against IPA and the permissive niche generated through immunosuppression.
HIGHLIGHTS
Host-pathogen immune response is visualized in vivo and quantified against IPA Modified PFC-based nanoparticles were used for in vivo labeling of immune cells Clinical immunosuppression depict dynamic immune response upon fungal challenge 19 F MRI showed follow-up of labeled immune cells in individual animals over time
INTRODUCTION
Aspergillus fumigatus is an opportunistic, potentially life-threatening fungus, which thrives mainly on organic substrates like decaying vegetation in the soil or food. Although environmental exposure of humans to the airborne A. fumigatus conidia is common, host-pathogen interactions effectively eradicate conidia from the pulmonary region of healthy individuals (Margalit and Kavanagh, 2015; Mccormick et al., 2010) . The key determinant of infection is thought to be the innate immune response. A. fumigatus conidia in the alveolar space of lungs trigger pathogen recognizing receptors (PRRs), driving the first responders of the immune system (Dagenais and Keller, 2009) . Key cellular mediators of immunity include resident alveolar macrophages, monocytes and dendritic cells for the engulfment of conidia, and neutrophils for the destruction of hyphae using neutrophil extracellular traps (Khanna et al., 2016; Roilides et al., 1998; Sales-campos et al., 2013; Zhang et al., 2019) .
Healthy individuals effectively clear A. fumigatus, whereas infection becomes life-threatening in immunocompromised patients. With an increasing number of immunocompromised patients from organ transplantation or cancer treatment, invasive pulmonary aspergillosis (IPA) is rapidly growing as a medical problem (Berenguer et al., 1995) . The acute inflammation in the lungs of patients with IPA suggests an underlying malfunction, rather than absence, of essential host immune components as the causative factor (Krenke and Grabczak, 2011) . The modus operandi for the clinical use of immunosuppressive drugs mainly includes cyclophosphamide (CY) (Emadi et al., 2009) and hydrocortisone acetate (HCA) (Garth and Steele, 2017; Shaikh et al., 2012) administered intravenously to the patients. In previous studies, it was shown that the pathophysiology of IPA and the immune response against the fungal infection differs for each compounds (Dagenais and Keller, 2009; Stephens-Romero et al., 2005) . Corticosteroids treatment impairs phagocyte function, including an abnormality in cellular migration and production of the inflammatory cytokines, while leaving neutrophils intact and functional (Brummer et al., 2001; Kamberi et al., 2002; Nawada et al., 1996) . The phagocytic defect permits infection growth, which in turn drives a massive recruitment of neutrophils to the site of infection, resulting in intensive tissue damage. By contrast, CY induces neutropenia and depletes other circulating white blood cells, while leaving the local innate immune response relatively intact. Here the neutropenia is thought to be critical in permitting hyphal growth and further invasion in the tissue (Jones et al., 2019; Kalleda et al., 2016) . A key limitation of these conclusions, however, is the reliance on invasive methods that are restricted to single time point measurements, such as immunohistochemistry (Balloy et al., 2005; Wang et al., 2017) . Knowledge of immune kinetics and longitudinal disease progression is currently lacking but is essential for understanding the dynamics of these processes (Kalleda et al., 2016) . In vivo imaging techniques are potentially able to assess the host response against the infection longitudinally in individual animals. Different imaging techniques have been used in preclinical models to characterize IPA, such as computed tomography, positron emission tomography, bioluminescence imaging, single photon emission tomography, proton magnetic resonance imaging ( 1 H MRI), and fibered confocal fluorescence microscopy (Brock et al., 2008; Poelmans et al., , 2018 Rolle et al., 2016; Vanherp et al., 2018; Wang et al., 2013) . Although these approaches fulfill the non-invasive and longitudinal criteria required, they lack specific information on inflammatory processes occurring in the host. In other disease models, ex vivo and in vivo cell labeling approaches use 1 H MRI contrast agents to visualize immune cells for studying various inflammatory processes (De Temmerman et al., 2014; Ho and Hitchens, 2004; Schwarz et al., 2012; Wu et al., 2006) . However, 1 H MRI contrast agents such as (super)paramagnetic nanoparticles generate unspecific signal voids, making it difficult to locate and quantify labeled cells in vivo. Fluorine contrast agents in combination with 19 F MRI may provide an alternative, with specific and quantifiable contrast (Ebner et al., 2010; Srinivas et al., 2010a; Zhong et al., 2015) . 19 F MRI is an emerging non-invasive tool, which can be applied both for imaging of ex vivo contrast agent labeled cells after their transplantation and for in vivo labeling of cells after systemic administration of fluorinated contrast agents (Jacoby et al., 2014b; Srinivas et al., 2012 Srinivas et al., , 2010b . Using fluorinated contrast agents such as perfluoro-15-crown-5-ether nanoparticles (PFCE-NPs) in combination with 19 F MRI, one can generate highly specific MR contrast, owing to the lack of background signal. Overlaying the 19 F MR image with a conventional 1 H MR image provides the necessary anatomical background (Liang et al., 2018) .
Here, we developed an imaging platform allowing non-invasive and longitudinal quantification of the degree of pulmonary inflammation in IPA murine models. We showed that the in vivo labeling of immune cells with newly developed zonyl perfluoro-15-crown-5-ether nanoparticles (ZPFCE-NPs) reveal underlying pathophysiological events during acute IPA using 19 F MRI.
RESULTS

Small-Sized Biocompatible ZPFCE-NPs Showed Efficient In Vitro Labeling of Murine Phagocytes
To monitor the immune responses in vivo, we sought to exploit the functional property of phagocytosis for immune cells labeling. ZPFCE-NPs label professional phagocytic cells owing to their small size (Waiczies et al., 2011) . To validate the feasibility of this strategy, Macrophages, identified by their characteristic high surface expression of CD11b and F4/80, successfully phagocytosed ZPFCE-NPs in a dose-dependent manner (Figure 1 ). ZPFCE-NP labeling of macrophages showed similar labeling efficiencies for particle concentrations of 1 and 10 mM ( Figure 1A ). We used ZPFCE-NPs incorporated with Cholesteryl BODIPY FLC 12 green fluorescent dye. These nanoparticles did not show nanotoxicity in primary macrophages upon labeling with relatively high concentrations, affirming their suitability for in vivo applications ( Figure S1 ).
A key requirement for an in vivo labeling protocol is that the label does not interfere with the biological processes being measured. To investigate whether ZPFCE-NP labeling modulates macrophage function, we tested key innate and adaptive functions in vitro. Using cytokine secretion as a readout for innate functional activation of macrophages, we found no impact of ZPFCE-NPs on spontaneous or lipopolysaccharide (LPS)-induced immune activation at a dose of 1 mM and only a weak enhancement of LPS-induced TNF-alpha production at 10 mM (Figure 2A ). For the adaptive immune system, we tested the biological effect of ZPFCE-NPs labeling on antigen-presentation by macrophages. C57BL/6 peritoneal macrophages were pre-labeled with ZPFCE-NPs and pulsed with OVA peptide (OVA323-339) before co-culture with OVA-reactive OT-II TCR transgenic CD4+ T cells. OT-II T cells showed efficient activation when primed with OVA-loaded macrophages, which was unaltered by the pre-loading with ZPFCE-NPs ( Figure 2B ). Together, these results demonstrate that 1 mM ZPFCE-NPs allow macrophage labeling without inducing biological alterations to either the innate or adaptive functions of macrophages.
F MRI Allows In Vivo Visualization and Quantification of Immune Cell Recruitment in A. fumigatus-Infected Lungs
Having validated ZPFCE-NPs as an efficient and biologically neutral contrast agent for macrophages, we sought to assess the in vivo utility using IPA mouse models to apply our methodology as a proof of principle. To test the robustness of our immunomonitoring method, we used three models of pulmonary aspergillosis with immunocompetent and immunosuppressed mice, together with non-infected mice as control. CY or HCA immunosuppressive drugs were used to induce neutropenia and phagocytic dysfunction in mice, respectively. Immunocompetent mice infected with A. fumigatus demonstrated a large and rapid influx of macrophages into the lung within 4 h of infection ( Figure 3A , second row and 3B). Inflammation was quickly resolved, with a return to near-baseline macrophage levels by 24 h ( Figure 3B ). By contrast, both forms of immunosuppression sharply reduced the immediate innate response to infection, with poor influx at 4 h ( Figure 3A , third and fourth row and 3B). In both cases, this defect in the immediate response corrected with a more chronic inflammatory signal, with large macrophage influx out to at least 3 days post infection ( Figure 3B ), consistent with a model where the defective immediate response allowed infection to become invasive and chronic. We observed and quantified a higher fluorine MRI signal intensity in the HCA mice as compared with the CY mice groups at the site of inflammation post pulmonary infection. No detectable fluorine signal was observed from the non-infected immunocompetent mice (N-IC).
Key differences were also observed between the immunosuppressed groups, with HCA-treated mice but not CY-treated mice, resulting in a transient flux of macrophages into the cervical lymph nodes on day 1 post infection ( Figure 3C ). This indicates that HCA allows macrophage mobilization but diverts recruitment into the draining lymph node rather than into the tissue.
To monitor progression of infection, we applied a cumulative scoring of 1 H MR images based on the lung signal intensity in all murine groups. This shows the pathophysiological changes occurring over time following infection from day of infection (day 0) until day 3 ( Figure S2A ). We have observed high signal intensities in the CY group where infection was more profound compared with the HCA group ( Figure S2B ). Together, these results both validate 19 F MRI as an in vivo monitoring tool for anti-microbe responses and indicate a critical window of response for the innate immune system against A. fumigatus invasive infection.
Distinctive Fungal Burden Depicted by Bioluminescent Imaging and Colony-Forming Units Confirms Infection
To affirm infection and viable pulmonary fungal load with inflammatory processes that we have monitored by 19 F MRI, we have examined the Fluc + A. fumigatus infection 3 days after infection by using ex vivo bioluminescent imaging (BLI). After D-luciferin administration in the lungs, CY-treated mice showed higher BLI signal intensity compared with the hydrocortisone-treated mice ( Figure 4A ). No detectable bioluminescence signal was observed from the lungs in the two control groups, infected immunocompetent and non-infected mice. Quantification of BLI signal also showed significantly high fungal infection in the CY-treated group compared with the hydrocortisone-treated group and infected-immunocompetent group ( Figure 4B ). This indicates strong invasion of fungi in the lungs of the CY group owing to lack of an efficient immune response compared with the HCA group, where the immune response prevents the growth of A. fumigatus.
For the quantification of pulmonary fungal load, we performed colony-forming unit (CFU) counting on the cultured lung homogenates from all mice groups. We observed a significant increase in the A. fumigatus burden in the lungs of the CY group when compared with the HCA on day 3 ( Figure 4C ). In contrast, N-IC and I-IC groups did not show any fungal growth. These results together with 19 F MRI suggest the early immune activation in infected mice as a critical aspect for the control of potentially invasive A. fumigatus progression.
Validation of ZPFCE-NP-Labeled Immune Cell Recruitment in the Lungs and Lymph Nodes by Histology and Immunofluorescence Imaging
To validate our imaging results, we performed periodic acid-Schiff (PAS) staining and immunofluorescence after sacrificing the animals 3 days after infection. Similar to 19 F MRI, we observed high pulmonary (B) C57BL/6 peritoneal macrophages were pre-loaded with ZPFCE-NPs and pulsed with OVA peptide (OVA 323-339 ) at different concentrations, before co-culture with OT-II TCR transgenic CD4+ T cells. After 3 days of co-culture, the cells were stained for lineage T cell markers in combination with T cell activation markers and analyzed by flow cytometry. The percentage of CD44 high CD62L low activated T cells across variable doses of the OT-II peptide, for ZPFCE-NP-labeled and unlabeled macrophages (mean G SEM). inflammation in the lung tissue of the HCA group upon A. fumigatus challenge with minimal fungal invasion. In contrast, the CY group, showed as expected fungal growth and hyphal growth formation with invasion in nearby tissues and no visible inflammation ( Figure 5A ). The two control N-IC and I-IC mice groups showed normal lung tissue morphology with no fungal infection on day 3, validating the 19 F MRI findings.
Immunofluorescence images also showed the presence of stringent inflammation resulting in higher influx of ZPFCE-NP-labeled macrophages and dendritic cells in the lungs of the HCA group in contrast (C) 19 F MRI signal was observed from the lymph node region only for mice from the HCA group on day 1. Mean 19 F MR signal intensity was quantified with respect to the 30 mM reference placed next to each animal. 19 F MRI signal in lymph nodes is indicated as hot spots overlaid over the anatomical 1 H MR image (right panel). Data shown as mean G SEM ( * p < 0.05).
to the CY group ( Figure 5B , third and fourth row). Additionally, elevated recruitment of granulocytes was observed near the airways of the HCA group compared with other groups. The N-IC and I-IC groups showed no visible inflammation or infection similar to 19 F MRI ( Figure 5B , first and second row). We also noticed differences in white blood cell counts, analyzed individually from the peripheral blood of different groups on day 3, indicating severe inflammation in the HCA group reflected by an increase in the number of neutrophils and lymphocytes in the blood in contrast to the CY group ( Figure S3 ). The non-infected model showed similar levels of neutrophils and lymphocytes as the I-IC model where immune cells were in the normal range. Notably, the cervical lymph nodes of the HCA group showed high ZPFCE-NPs accumulation ( Figure S4 ). ZPFCE-NPs were also visualized in the OCT (optimum cutting temperature)-embedded lungs on day 3 by ex vivo fluorescence imaging illustrating high fluorescent signal observed both in the lungs and cervical lymph nodes, only in the HCA group ( Figure S5 ). Briefly, these results strongly support the 19 F MRI findings, demonstrating the feasibility of our established methodology for non-invasive monitoring of infection.
DISCUSSION
With the increased number of immunocompromised patients, it becomes more important to closely monitor those patients, diagnose, and follow up IPA. Among the profound number of clinical IPA cases, 90% are caused by A. fumigatus (Lin et al., 2001; Massam et al., 2011) . For a better understanding of aspergillosis and for testing of novel antifungal compounds, preclinical animal models are essential. Although methods for monitoring the dynamics of the immune cells upon A. fumigatus infection have been developed recently (Kalleda et al., 2016) , these studies were not able to assess the interaction with the host's immune system longitudinally in vivo. Here, we have developed an approach that allows the non-invasive, dynamic monitoring of both inflammatory processes and the infection in three different animal models of IPA. Several cell-labeling approaches have been established to non-invasively visualize the mechanisms of immune reactions involved in various diseases by tracking the loci of inflammatory immune cells using 19 F MRI (Ebner et al., 2010; Flogel et al., 2008; Jacoby et al., 2014a; Stoll et al., 2012) . In this study, we focused on the quantification and localization of inflammation in IPA murine models of immune impairments induced by clinically used immunosuppressive drugs (Balloy et al., 2005; Stergiopoulou et al., 2007; Woodruff and Hebert, 2002) . PFCs have been used and tested as blood substitutes and thus proven to be safe in humans (Janjic and Ahrens, 2009; Ruiz-Cabello et al., 2011) . Here, we synthesized ZPFCE-NPs and studied their potential for the labeling of phagocytic immune cells. It has been shown that labeling with PFCE particles of different sizes could potentially modulate the immune function of dendritic cells (Waiczies et al., 2011) . In this study, we showed the biological compatibility of ZPFCE-NPs for in vivo studies, where labeled macrophages retained their antigen processing and T cell activation capacity. Compared with most other PFCs, ZPFCE-NPs have a reduced size of 280 nm .In our in vivo study, we have used 19 F MRI to quantify inflammation non-invasively and longitudinally after systemic injections of ZPFCE-NPs. The 19 F MRI signal detected in inflamed areas corresponds to the infiltration of labeled phagocytic cells in the region of interest (Flogel et al., 2008; van Heeswijk et al., 2015) . We observed high 19 F MRI signal intensities in the lungs of the infected immunocompetent (I-IC) mice already 4 h after the fungal infection, which was completely cleared after 24 h, confirming the expected eradication of A. fumigatus conidia by the immune system. In the hydrocortisone (HCA)-treated mice, the exacerbated intrusive recruitment of immune cells resulted in the labeling of not only tissue-resident macrophages but also dendritic cells (Temme et al., 2012) . Inflammation was found to be less pronounced in the CY-treated mice, with increased fungal invasion in the lungs. We did not observe any detectable fluorine signal in the lungs from the non-infected immunocompetent (N-IC) mice that have received ZPFCE-NPs, indicating absence of any inflammation in the lungs. Only in HCA mice, elevated accumulation of ZPFCE-NPs was observed in the nearby cervical lymph nodes to 3 days after infection as shown in the 19 F MR images.
In addition to 19 F MRI, in vivo 1 H MRI in these mouse models was able to document the lesion development occurring in the lungs upon fungal conidia challenge. As shown by our quantitative image analysis, we observed high lung lesion formation in CY mice two and three days after infection, which is consistent with profound fungal hyphal growth and invasion in lungs as reported before . 1 H MRI indicated only weak lesion formation in the infected HCA-treated and I-IC groups. These results endorse the fact that the administration of CY as a frequently used immunosuppressive drug can lead to lethal IPA with mild initial inflammation in the lungs as indicated by 19 F MRI. On the contrary, hydrocortisone-based immunosuppression leads to less lesion formation by A. fumigatus but triggers acute inflammation leading to potentially lethal tissue destruction (Kalleda et al., 2016) . The functional immune system of the infected-immunocompetent mice resulted in the rapid initial immune reaction and complete clearance of the fungi as shown in the 1 H MR images and also confirmed by histology. By using 19 F MRI, we were able to monitor the intricate dynamic profile of the host-pathogen interaction in pulmonary A. fumigatus infection in vivo. We documented the differences between immunocompetent hosts and animals treated with two different immunosuppressive compounds. With clinically safe contrast agents like perfluorocarbon (PFC)-based fluorinated nanoparticles, 19 F MRI not only proved to be a powerful imaging modality for numerous preclinical studies but also showed potential for translation to humans. For immune cell imaging, 19 F MRI has developed into a robust method for the follow-up of phagocytic cells with less success in the tracking of non-phagocytic cells owing to the sensitivity issues of 19 F MRI (Saini et al., 2019) .
In summary, we demonstrated the potential of 19 F MRI and perfluorocarbon-based ZPFCE-NPs by successful tracking and quantifying the fluorine signal generated by innate immune cells, macrophages, and dendritic cells in the lungs corresponding to the intensity of local inflammation. By being able to monitor both the infection and immune reaction in live animals over time, it is possible to make treatment decisions rapidly and almost in real time. In the future, this will help in testing transgenic fungal strains, novel antifungal drugs, or new approaches to influence the immune system. Overall, it will provide an emerging 19 F MRI platform for studying not only basic mechanisms of fungal infections but also advanced immune cell therapies in patients (Ahrens et al., 2014; Amiri et al., 2015; Fink et al., 2018; Hertlein et al., 2013) .
Limitations of the Study
Although the PFC-based fluorinated nanoparticles provided specific contrast for immune cell imaging in the preclinical aspergillosis models, 19 F MRI is still limited to applications where large cell numbers accumulate locally. For less severe models of inflammation, the sensitivity of 19 F MRI needs to be improved by using either contrast agents with higher fluorine load or improved hardware (Khalil et al., 2019) and/or image processing approaches (Liang et al., 2017) . In addition, in vivo cell labeling was restricted to phagocytic cells like macrophages. Animal models used in this study were already described by invasive methods. In the future, a comparative experiment using a PRR knockout mouse strain instilled with a transgenic fungus lacking a key PAMP (e.g., melanin or galactosaminoglycan) can be used as a suitable model to study the immune response in differently modulated transgenic animals.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
SUPPLEMENTAL INFORMATION
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Transparent method section
Animals
For the in vitro labeling experiments, macrophages were isolated from the peritoneum of C57/BL6 female mice (8-9 week-old). Female OT-II mice (6-8-week-old) bearing the MHCIIrestricted T cell receptor (TCR) for OVA323-339 were bred in house. For in vivo experiments, 10-week-old male Balb/c mice (Janvier, Le Genest, France) were housed in KU Leuven animal housing facility with free access to food and water.
All animal experiments were approved by the Ethical Committee of KU Leuven and were 
Synthesis of fluorinated Zonyl-PFCE nanoparticles
The synthesis of biochemically inert perfluoro-15-crown-5-ether (PFCE) nanoparticles consisting of a PFCE liquid core emulsified by a monolayer of phospholipids was performed as described previously . The fluorosurfactant Zonyl ® FSP (Du Pont, Delaware, USA) was incorporated in the lipid shell of PFCE nanoparticles, obtaining nanoparticles with an average size of 280nm. For the in vitro and in vivo experiments, ZPFCE-NPs were coupled with either Cholestryl BODIPY ® FLC12 or DiR fluorescent dye (both from Molecular Probes, Invitrogen, Merelbeke, Belgium).
In vitro labeling of macrophages using ZPFCE nanoparticles
For in vitro labeling, cells were incubated with ZPFCE-NPs at fluorine concentration of 0.5, 1 and 10mM for 1h at 37°C in 5% CO2 in ultra-low attachment plates (Corning Costar, Kennebunk, ME, USA). For positive selection of labeled macrophages, cells were analyzed for surface marker expression after pre-incubation with the Fc receptor blocking antibody anti-CD16/CD32 (eBioscience, San Diego, CA, USA) and staining using anti-F4/80 and anti-CD11/b (eBioscience, San Diego, CA, USA) to perform quantitative flow cytometric analyses.
Toxicological assay on ZPFCE-NP labeled macrophages
Primary macrophages were labeled with different concentrations of ZPFCE-NPs. Surface staining with anti-F4/80 (eBiosciences) was performed to identify macrophages by microscopic analysis. Following exposure to nanoparticles, immune cells were stained to assess cell viability, cytoskeletal changes and oxidative stress. Data analysis was performed using a highcontent InCell 2000 analyzer (GE Healthcare Life Sciences, Diegem, Belgium) as previously described (Manshian et al., 2014) .
Determination of cytokine secretion by ZPFCE-NP labeled macrophages
For cytokine measurement, ZPFCE-NP labeled macrophages were co-cultured in the presence or absence of 1µg/mL lipopolysaccharides (Sigma Aldrich, Overijse, Belgium) for 24h.
Supernatants were collected and measurements of IL-10, IL-1beta and TNF-alpha were performed using a customized MSD V-PLEX mouse proinflammatory kit (Mesoscale, Maryland, USA). Readings were performed using a MESO QuickPlex SQ120 plate reader (Mesoscale, Maryland, USA).
In vitro adaptive immune test on ZPFCE labeled macrophages
Splenocytes from OTII transgenic mice were homogenized and negative selection of purified total CD4+ T cells was performed using a cocktail of antibodies for CD16/CD32, CD11b, CD11c, B220, MHC-II and CD8 markers. Contaminating, bead-bound cells were removed using sheep-anti-rat IgG paramagnetic beads, according to the manufacture's specifications (Dynabeads, Invitrogen Merelbeke, Belgium) . Purity of samples (>95%) was routinely assessed by flow cytometry. Purified OTII-transgenic CD4+ T cells were co-incubated with ZPFCE-NP labeled macrophages in a 96 well plate together with variable doses of anti-TCR b5.1/b5.2 (OTII) peptide at concentrations of 0, 0.1, 1, 10μg/ml for 1-3 days at 37°C under 5% CO2 for 1h. To prevent non-specific binding all surface stains were performed in the presence of anti-CD16/CD32. For macrophages, the antibodies F4/80-PerCPCy5.5, CD45-APC-eFluor780 and CD11b-eFluor450 were used. To stain T cells, CD44-FITC, TCRb5.1/5.2-PE, CD62L-Per CPCy5.5, CD69-PECy7 and CD4-eFluor450 were used to assess effector, memory and naïve CD4+ T cell subsets using flow cytometry. All antibodies were purchased from eBioscience (San Diego, CA, USA).
Murine models of invasive pulmonary aspergillosis
To develop a non-neutropenic IPA model, mice were injected subcutaneously (s.c.) with 9mg hydrocortisone acetate per 25g body weight (Sigma-Aldrich, USP, Overijse, Belgium ) one and three days before inoculation with A. fumigatus (HCA group, n=9). To induce neutropenia, 200mg kg -1 body weight cyclophosphamide (Sigma-Aldrich, USP, Overijse, Belgium) was injected intraperitoneally (i.p.) one and three days before inoculation with A. fumigatus (CY group, n=9) . Infected immunocompetent mice (I-IC group, n=4) and non-infected immunocompetent mice (N-IC, n=3) were included as control groups.
The Fluc + A. fumigatus strain 2/7/1 was generously provided by M. Brock (School of Life Sciences, University of Nottingham, UK). The strain was cultured and conidia were harvested using a previously described protocol . On day of infection (day 0), HCA and infected immunocompetent groups (I-IC group, n=4) were intranasally instilled with 1×10 6 spores. The CY group was inoculated with 5×10 5 spores based on the protocol described previously . ZPFCE-NPs were administered via tail vein 1h prior to MRI acquisition on day 0 and day 1. On the day of inoculation (day 0), MRI experiments were performed on all mice groups 4h after the administration of spores. All murine groups were monitored for weight loss and posture changes starting from day 0 to detect onset of disease symptoms and to define the humane end-points.
Longitudinal in vivo fluorine ( 19 F) magnetic resonance imaging
Animals were anesthetized by intraperitoneal (i.p.) injections of ketamine (45-60 mg kg -1 ,
Nimatek, Eurovet animal health, Bladel, The Netherlands) and Medetomidine (0.6-0.8 mg kg -1 , Domitor, The Orion Pharma, Espoo, Finland) solution. In vivo longitudinal follow-up of all murine groups was performed using 1 H and 19 F MRI on a 9.4T preclinical MRI scanner (Bruker Biospec 94/20, Ettlingen, Germany). After the MR acquisition, injections of atipamezole (Antisedan, The Orion Pharma, Espoo, Finland) were administered i.p. to reverse the effects of anesthesia. Throughout the MR imaging experiments, body temperature and respiration rate of the animals were monitored and maintained to 37°C and 60-80 min -1 , respectively.
A purpose-built dual-tuned radio frequency surface coil was used to acquire fluorine and 1 H MR images. For all in vivo MRI experiments, 2D RARE (Rapid Acquisition with Relaxation Enhancement) MRI was performed using the following acquisition parameters: 1 H MRI, repetition time (TR) = 3500ms, echo time (TE) = 6.12ms, spatial resolution = 0.156mm×0.156mm, slice thickness = 1mm. For 19 F MRI, TR = 5388ms, TE = 6.11ms, spatial resolution = 1.25mm×1.25mm, slice thickness = 2mm were used. A reference tube containing 30mM of ZPFCE-NPs embedded in agar was placed next to the abdomen of the animal during the MR acquisition to allow quantification of fluorine atoms. For both 1 H and 19 F MR images, data were acquired with the same localization (placement, orientation of slice packages).
Quantification of 19 F MR signal and data processing
Prior to the MR signal quantification, images were reconstructed using the Paravison 5.1 software (Bruker Biospin, Ettlingen, Germany). For post processing, MR images were exported to the MeVislab software version 2.6.1 (MeVis Medical Solutions AG, Bremen, Germany).
Gaussian smoothing was applied to the 19 F MR images. Before masking the fluorine images, interval thresholding was performed by applying a value higher than the background noise.
Masked 19 F MR images were rescaled to the same matrix size as the 1 H MR images before superimposing them over each other. To calculate the amount of fluorine atoms/voxel, the processed 19 F MR images were analyzed slice-wise using the Fiji software, version 1.49a (South Carolina, USA) by drawing the region of interests on the fluorine hot spots in the lungs and the lymph node regions, which were identified based on the anatomical 1 H MR images. For quantification, regions were compared with the reference tube that contained 30mM ZPFCE-NPs. Cumulative 1 H image scoring was performed on 1 H images of all murine groups from day 0 to day 3. Based on the visual observations, lung lesions were identified and a scoring system was used to assign a value for the quantification of signal intensities corresponding to the disease development as described previously (Petraitiene et al., 2002; Petraitis et al., 2003) .
Ex vivo bioluminescence imaging
On day 3, the animals were euthanized and the lungs were inflated with 0.5ml D-luciferin (7.5mg) (Promega, Leiden, The Netherlands) by inserting a 22-gauge catheter (Terumo, Heverlee, Belgium) into the trachea. The lungs were immediately placed into the flow chamber to perform ex vivo BLI acquisitions on the IVIS Spectrum imaging system (Perkin Elmer, Massachusetts, USA). Data were analyzed using Living Image ® software version 4.5.5 (Perkin Elmer, Massachusetts, USA).
Differential white blood cell measurements
For the differential blood cell counting, mice were euthanized under deep terminal anesthesia and blood was withdrawn using a 25-gauge needle (Terumo, Heverlee, Belgium) from the left ventricles of the beating heart through cardiac puncturing. Total collected blood volume was 0.3 ml from each mouse. To prevent coagulation of blood, 30µl of tri-sodium citrate, 3.8% w/v (VWR, Belgium) was added to the blood collection tubes. Blood cell counts were performed on an ADVIA ® 2120i hemocytometer, version 5.4 (Siemens Healthcare, GmbH, Erlangen, Germany).
Colony-forming unit (CFU) measurements
After the ex vivo BLI acquisition, the right lung lobes were collected in 600µl PBS and homogenized to obtain suspensions of lung tissue. Lung homogenates were plated on Sabouraud agar, followed by an incubation period of 2-3 days at 30°C for manual counting of CFUs.
Flow cytometry and microscopy
Flow cytometry acquisitions were performed on a Gallios TM flow cytometer (Beckman Coulter, Brea, California, USA). For the data analyses, a FlowJo software, version 10.4.2 (FlowJo LLC, Ashland, Oregon, USA) was used. Microscopic images were acquired using a confocal microscope (Nikon, Tokyo, Japan) and analyzed using Fiji software, version 1.49a (South Carolina, USA).
Ex vivo optical imaging of lungs and cervical lymph nodes
Ex vivo fluorescence imaging was performed on the lungs and cervical lymph nodes (LN) of all animals using the IVIS Spectrum imaging system (Perkin Elmer Massachusetts, USA). For the acquisition of data, parameters used are as following: exposure time = 10sec, 740nm excitation and 800nm emission filters with medium binning. Data analysis was performed using the Living Image ® software, version 4.5.5 (Perkin Elmer, Massachusetts, USA).
Histology and immunohistochemistry
Right lung lobes were fixed in 4% PFA and embedded in paraffin. For visualization of fungi, lungs were sectioned (5µm) and stained with Periodic acid-Schiff (PAS) agent as described . Brightfield images were acquired using ZEISS Axio Scan.Z1 Digital Slide Scanner (Carl Zeiss, Oberkochen, Germany). For immunoflurosence, left lung lobes were fresh frozen in OCT (optimum cutting temperature) formulation and cryosections (11µm) were fixed in 4% paraformaldehyde and stained according to manufacturer's protocol. For staining of the sections following monoclonal antibodies were used: GR1 (RB6-8C5, eBioscience), CD11b (M1/70, Biolegend), CD11c biotin (N418, eBioscience). For the staining of immune cells, the following detection antibodies were used: Donkey anti-Rat 488, Streptavidin 546, (all from Molecular Probes). Images were acquired using a EVOS FL Auto 2 microscope (Fisher Scientific, Merelbeke, Belgium).
Statistical analysis
For statistical analyses, One-way and Two-way ANOVA tests were performed together with Bonferroni multiple comparison test to compare the different animal groups using the GraphPad Prism software ® , version 5.04 (La Jolla, CA, USA).
